ContactCredit ReportFinancialsPeopleOwnershipLatest ActivityMutual CompaniesDocumentsRepayment History

Kiniksa Pharmaceuticals (UK), Ltd

Kiniksa Pharmaceuticals (UK), Ltd is an active company incorporated on 6 December 2018 with the registered office located in London, Greater London. Kiniksa Pharmaceuticals (UK), Ltd was registered 6 years ago.
Status
Active
Active since incorporation
Company No
11716038
Private limited company
Age
6 years
Incorporated 6 December 2018
Size
Large
Turnover is over £54M
Balance sheet is over £27M
Confirmation
Submitted
Dated 5 December 2024 (10 months ago)
Next confirmation dated 5 December 2025
Due by 19 December 2025 (1 month remaining)
Last change occurred 10 months ago
Accounts
Submitted
For period 1 Jan31 Dec 2024 (1 year)
Accounts type is Audit Exemption Subsidiary
Next accounts for period 31 December 2025
Due by 30 September 2026 (11 months remaining)
Address
Kiniksa Pharmaceuticals (Uk) Ltd,
Third Floor, 23 Old Bond Street
London
W1S 4PZ
United Kingdom
Address changed on 10 Mar 2022 (3 years ago)
Previous address was
Telephone
Unreported
Email
Unreported
People
Officers
6
Shareholders
1
Controllers (PSC)
1
Director • British • Lives in UK • Born in Oct 1980
Director • American • Lives in United States • Born in Apr 1974
Director • British • Lives in England • Born in May 1980
Director • British • Lives in England • Born in Jun 1981
Secretary
Shareholders, PSCs & Group Structure
See who truly controls a company with full PSC, Shareholder, and Group Structure exploration
Mutual Companies
Kiniksa Pharmaceuticals International, Plc
Ross Michael Moat is a mutual person.
Active
Financials
Net Assets, Total Assets & Total Liabilities (2019–2024)
Period Ended
31 Dec 2024
For period 31 Dec31 Dec 2024
Traded for 12 months
Cash in Bank
£99.92M
Increased by £45.22M (+83%)
Turnover
£344.32M
Increased by £131.4M (+62%)
Employees
13
Increased by 1 (+8%)
Total Assets
£799.96M
Increased by £26.4M (+3%)
Total Liabilities
-£105.11M
Increased by £39.17M (+59%)
Net Assets
£694.86M
Decreased by £12.77M (-2%)
Debt Ratio (%)
13%
Increased by 4.62% (+54%)
Latest Activity
Subsidiary Accounts Submitted
24 Days Ago on 27 Sep 2025
Madelyn Demsky Zeylikman Resigned
1 Month Ago on 17 Sep 2025
Mr Douglas Barry Appointed
1 Month Ago on 17 Sep 2025
Adam William Burgess Resigned
1 Month Ago on 12 Sep 2025
Confirmation Submitted
10 Months Ago on 9 Dec 2024
Full Accounts Submitted
1 Year Ago on 6 Oct 2024
Ross Michael Moat Resigned
1 Year 2 Months Ago on 1 Aug 2024
Kiniksa Pharmaceuticals, Ltd. (PSC) Resigned
1 Year 3 Months Ago on 27 Jun 2024
Kiniksa Pharmaceuticals International, Plc (PSC) Appointed
1 Year 3 Months Ago on 27 Jun 2024
Confirmation Submitted
1 Year 9 Months Ago on 12 Jan 2024
Get Credit Report
Discover Kiniksa Pharmaceuticals (UK), Ltd's Credit Score, how much credit you can offer them, and how likely they are to repay you
Documents
Notice of agreement to exemption from audit of accounts for period ending 31/12/24
Submitted on 27 Sep 2025
Audit exemption statement of guarantee by parent company for period ending 31/12/24
Submitted on 27 Sep 2025
Consolidated accounts of parent company for subsidiary company period ending 31/12/24
Submitted on 27 Sep 2025
Audit exemption subsidiary accounts made up to 31 December 2024
Submitted on 27 Sep 2025
Appointment of Mr Douglas Barry as a secretary on 17 September 2025
Submitted on 17 Sep 2025
Termination of appointment of Madelyn Demsky Zeylikman as a secretary on 17 September 2025
Submitted on 17 Sep 2025
Termination of appointment of Adam William Burgess as a director on 12 September 2025
Submitted on 17 Sep 2025
Confirmation statement made on 5 December 2024 with updates
Submitted on 9 Dec 2024
Full accounts made up to 31 December 2023
Submitted on 6 Oct 2024
Termination of appointment of Ross Michael Moat as a director on 1 August 2024
Submitted on 20 Aug 2024
Repayment History
Understand how businesses repay their debts and see how they're performing year‐on‐year